Home › NDC Lookup › RxCUI directory › RxCUI 1740865

2 ML fludarabine phosphate 25 MG/ML Injection — RxCUI 1740865

RxNorm drug concept · Semantic clinical drug
RxCUI 1740865 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1740865
Official name2 ML fludarabine phosphate 25 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asfludarabine phosphate 50 MG per 2 ML Injection; fludarabine phosphate 50 MG in 2 ML Injection
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)44 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Fludarabine Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Fludarabine Injection is used to treat a type of blood cancer called B-cell chronic lymphocytic leukemia (CLL) — specifically in adults whose disease stopped responding to a previo...
  • What exactly is fludarabine being used to treat, and why is it given by IV?
  • Common side effects include low blood counts (which raise your risk of infection and bleeding), fever, chills, nausea, fatigue, and skin rash — these are expected and your team wil...
  • What side effects should I expect, and which ones should I call my doctor about right away?
📖 Read our full Fludarabine Injection guide →

🕸️ Concept Web — How 2 ML fludarabine phosphate 25 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 2 ML fludarabine phosphate 25 MG/ML Injection RxCUI 1740865

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Fludarabine 24698
    • Fludarabine phosphate 25102
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Fludarabine Injection 1740863
    • Fludarabine phosphate Injection 2646795
    • Fludarabine Injectable Product 1165043
    • Fludarabine phosphate Injectable Product 2659948
    • Injection 1649574
    • Injectable Product 1151126
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Fludarabine phosphate 25 MG/ML 328431

Showing up to 8 concepts per family — 9 of 9 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Fludarabine phosphate 25 MG/ML SCDC · 328431
  • Fludarabine Injection SCDF · 1740863
  • Fludarabine phosphate Injection SCDFP · 2646795
  • Fludarabine Injectable Product SCDG · 1165043
  • Fludarabine phosphate Injectable Product SCDGP · 2659948

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 1740865 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00527-1242-02 1 VIAL, SINGLE-DOSE in 1 CARTON (0527-1242-02) / 2 mL in 1... Fludarabine Phosphate Lannett Company, Inc. 2019-12-31
25021-0242-02 1 VIAL in 1 CARTON (25021-242-02) / 2 mL in 1 VIAL Fludarabine Phosphate Sagent Pharmaceuticals 2016-10-15
59923-0604-02 1 VIAL, SINGLE-DOSE in 1 CARTON (59923-604-02) / 2 mL in 1... Fludarabine Phosphate Areva Pharmaceuticals 2019-12-31
63323-0192-02 1 VIAL in 1 BOX (63323-192-02) / 2 mL in 1 VIAL Fludarabine Fresenius Kabi USA, LLC 2007-11-16
Observed labelers: Areva Pharmaceuticals (1) · Fresenius Kabi USA, LLC (1) · Lannett Company, Inc. (1) · Sagent Pharmaceuticals (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9185 Fludarabine phosphate inj 3 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.